TheStreet's Jim Cramer discussed several battered biotech stocks Friday while answering viewer questions from social media with TheStreet's Rhonda Schaffler.
A viewer asked about Regeneron Pharmaceuticals (REGN - Get Report) , particularly that there has been some insider buying recently and the stock is close to a 52-week low. Cramer responded, "Biotech stocks have been under such pressure. I'm not going to say don't buy Regeneron. I like it."
Cramer noted how Celgene (CELG - Get Report) Biogen (BIIB - Get Report) and Amgen (AMGN - Get Report) have all been slammed. Biogen is among the holdings of Action Alerts PLUS, the charitable trust portfolio managed by Cramer.
Cramer was asked about Oracle (ORCL - Get Report) . "I think Oracle is OK, but I like Salesforce.com (CRM - Get Report) . Salesforce has been winning business and you know what, I'm just feeling very confident about that (company).
A viewer wanted to know if Nestle (NSRGY) is a good long-term hold. "Not if the dollar has peaked, no," said Cramer.
Cramer does like Coca-Cola (KO - Get Report) , which he believes will move much higher. He also likes Pepsico (PEP - Get Report) , which is another holding of Action Alerts PLUS. "I like the snack business," said Cramer. "I like the combination of the two."